L
LENZ Therapeutics
A San Diego-based late-stage clinical company developing innovative ophthalmic pharmaceutical products to improve vision, with a focus on restoring presbyopia-related near vision loss
About LENZ Therapeutics
LENZ Therapeutics is a biopharmaceutical company in the late stages of clinical development, specializing in ophthalmic products to enhance vision. The company is currently focused on the development and commercialization of an aceclidine-based eye drop, known as LNZ100, which is the first of its kind designed to improve near vision in individuals with presbyopia.
As a pre-commercial entity, the company's primary activities revolve around research and development, clinical trials, and securing regulatory approvals for its products. The business model is centered on strategic licensing agreements with established pharmaceutical companies to commercialize its products in specific regions. This is evidenced by their recent exclusive agreements with Laboratoires Théa for the Canadian market and Lotus Pharmaceutical for Korea and other Southeast Asian countries. These agreements provide LENZ with upfront payments, milestone payments, and royalties on net sales, which will be their main source of revenue until their products are fully commercialized.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2021
- Headquarters
- Solana Beach, United States
- Listing
- IPO 2024
- Sector
- Biotech & Life Sciences
News
Open roles
LENZ Therapeutics in the Solana Beach ecosystem
The LENZ Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Versant Ventures
RA Capital Management
RTW Investments
Point72- AVAlpha Wave Ventures
Sectoral Asset Management
Series B and later1 investor entered at this stage
Ridgeback Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about LENZ Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See LENZ Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


